Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?

Study acronym: BIFI
StatusCompleted
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Lead sponsor: Jens Flensted Lassen to Aarhus University Hospital Skejby
    • Secondary endpoints: details revised at 1 of 2 entries
    v4
  3. Lead sponsor: Leif Thuesen to Jens Flensted Lassenv3
  4. Lead sponsor: Aarhus University Hospital Skejby to Leif Thuesenv2 Show 7 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 400 to 413
    • Primary completion date: Jun 2005
    • Study completion date: Aug 2006 to Mar 2011
    • Secondary endpoints: details revised at 2 of 2 entries
    • Collaborator revised
    • Study arms: 0 to 2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
How to use drug eluting stents (DES) in bifurcation lesions. A strategy of routine stenting of both main vessel and side branch versus a strategy of routine main vessel stenting and optional treatment of side branch. A randomized Nordic multicenter study including 400 patients with angina pectoris with clinical angiographic follow-up.
Trial Details
NCT Number NCT00376571
Lead Sponsor Aarhus University Hospital Skejby
Collaborators: Johnson & Johnson
Conditions
(from sponsor)		 Coronary Artery Disease
Related terms Coronary Artery Disease
Enrollment 413 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov